Table 2. Adverse Events by Reported Description for Both Treatment Groups.
| AEa | No. (%) | |
|---|---|---|
| Bimagrumab (n = 113) | Placebo (n = 67) | |
| Participants with ≥1 AE | 100 (88.5) | 52 (77.6) |
| Fall | 28 (24.8) | 24 (35.8) |
| Muscle spasms | 37 (32.7) | 10 (14.9) |
| Diarrhea | 22 (19.5) | 2 (3.0) |
| Hypertension | 9 (8.0) | 4 (6.0) |
| Contusion | 5 (4.4) | 7 (10.4) |
| Upper respiratory tract infection | 5 (4.4) | 5 (7.5) |
| Back pain | 5 (4.4) | 4 (6.0) |
| Pain in extremity | 6 (5.3) | 3 (4.5) |
| Headache | 5 (4.4) | 3 (4.5) |
| Nausea | 8 (7.1) | 0 |
| Bronchitis | 6 (5.3) | 2 (3.0) |
| Constipation | 6 (5.3) | 1 (1.5) |
| Urinary tract infection | 6 (5.3) | 1 (1.5) |
| Dizziness | 6 (5.3) | 0 |
| Increased lipase | 6 (5.3) | 0 |
| Osteoarthritis | 4 (3.5) | 2 (3.0) |
| Viral infection | 5 (4.4) | 1 (1.5) |
| Decreased appetite | 5 (4.4) | 0 |
| Fatigue | 5 (4.4) | 0 |
| Nasopharyngitis | 5 (4.4) | 0 |
| Rash | 5 (4.4) | 0 |
| Sinusitis | 4 (3.5) | 1 (1.5) |
| Increased amylase | 4 (3.5) | 0 |
| Cough | 4 (3.5) | 0 |
| Dysgeusia | 4 (3.5) | 0 |
| Dyspnea | 4 (3.5) | 0 |
| Vomiting | 4 (3.5) | 0 |
Abbreviation: AE, adverse event.
a
AEs with more than 3% in bimagrumab group have been listed.